ACHIKO-LTD.
Achiko Limited, a leading fintech provider in Indonesia, announced today that it plans to submit an application for a direct listing on the SIX Swiss Exchange, Switzerland's principal stock exchange.
Achiko's primary business is Mimopay. Founded in 2012, Mimopay has grown quickly to become a leading provider of payment services in Indonesia for people who do not have a bank account or credit card. People can pay for digital gaming content and services via a range of payment channels, such as telecom billing, game vouchers, and at over 10,000 convenience stores and over 100,000 ATMs.
"We're excited about the future and the opportunities that financial and digital inclusion can bring to the 1.7 billion unbanked adults around the world," said Allen Wu, Chairman of Achiko. "We're inspired by the success of platforms such as WeChat and Kakao, that combine payments with a wide- range of services, and believe that model provides a roadmap for our own global ambitions. We've started with Indonesia and we're expanding our system's digital and physical footprints by accelerating partnerships and diversifying revenue beyond payments."
The Company includes an experienced management team which has worked on and delivered multi-billion US dollar projects at globally-recognized digital businesses for companies such as Disney, Time-Warner, today named WarnerMedia, Samsung, Kakao and Leon Entertainment. With backing from MNC Corporation, Indonesia's largest media group, and MOX, the Mobile Only Accelerator of SOSV the first accelerator group in Asia, Achiko is redefining mobile based social commerce in one of the world's most vibrant consumer markets.
Building on Mimopay's 2 million end-user customers in Indonesia, Achiko intends to expand its payments platform through strategic partnerships in Myanmar, The Philippines and Vietnam, in the next 18 months. "There are many developing countries across the world like Indonesia that have high mobile penetration, yet a large population of unbanked who cannot pay for online services through traditional payment channels," said Kenneth Ting, the CEO of Achiko. "These markets represent tremendous growth opportunities for us."
The company plans to list 100 million shares. Achiko's last round of financing was at a USD $0.70 per share.
About Achiko Limited
The Holding Company was established in 2018, and includes Mimopay (2012), Kryptonite (2014), a licensee for the popular Yabb Messenger. The Company has operations in Indonesia, Korea and Taiwan, and is backed by MNC Corporation, the largest media company in Indonesia, and MOX, the Mobile Only Accelerator of SOSV -- the first mobile-focused accelerator in Asia.
For more information please visit: www.achiko.co
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005337/en/
Contact:
Axel Mühlhaus/ Dr. Sönke Knop Edicto GmbH Tel.: +49 69 905505-51 E-mail: achiko@edicto.de
Brigitte Kaps M: +41 (0) 79 289 2042 E-mail: pr@achiko.co
Shannon Chang VP Corporate Development, Achiko Limited E-mail: shannon.c@achiko.co
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom